Safety of ACE inhibitor therapies in patients with chronic kidney disease (Q34434606)

2 August 2017

title

Safety of ACE inhibitor therapies in patients with chronic kidney disease (English)

1 reference

2 August 2017

Grigory Sidorenkov

1

0 references

author name string

Gerjan Navis

series ordinal

2

1 reference

2 August 2017

language of work or name

English

0 references

publication date

22 August 2014

1 reference

Expert Opinion on Drug Safety

2 August 2017

published in

1 reference

2 August 2017

volume

13

1 reference

2 August 2017

issue

10

1 reference

2 August 2017

page(s)

1383-1395

1 reference

Angiotensin-converting enzyme inhibition and renal protection in nondiabetic patients: the data of the meta-analyses

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517/14740338.2014.951328

Treatment of chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2014.951328

Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers decrease the incidence of atrial fibrillation: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2014.951328

A meta-analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2014.951328

The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2014.951328

How does proteinuria cause progressive renal damage?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2014.951328

Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2014.951328

Angiotensin converting enzyme (ACE) inhibitors and kinin metabolism: evidence that ACE inhibitors may inhibit a kininase other than ACE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2014.951328

Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2014.951328

ACE inhibitors worsen inflammatory pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2014.951328

Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2014.951328

Sodium intake, ACE inhibition, and progression to ESRD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2014.951328

Improving the efficacy of RAAS blockade in patients with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2014.951328

Dietary sodium restriction: take it with a grain of salt

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2014.951328

Comparison of the pharmacokinetics of fosinoprilat with enalaprilat and lisinopril in patients with congestive heart failure and chronic renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2014.951328

Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2014.951328

Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2014.951328

Diarrhoea, vomiting and ACE inhibitors:--an important cause of acute renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2014.951328

Hyperkalemia: recognition and management of a critical electrolyte disturbance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2014.951328

Hyperkalemia associated with use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2014.951328

Pharmacogenetic predictors of angiotensin-converting enzyme inhibitor-induced cough: the role of ACE, ABO, and BDKRB2 genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2014.951328

Possible Angiotensin-Converting Enzyme Inhibitor (ACEI)-Induced Small Bowel Angioedema

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2014.951328

Angiotensin-Converting Enzyme Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2014.951328

ACE inhibitor-induced cough and bronchospasm. Incidence, mechanisms and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2014.951328

Angiotensin-converting enzyme (ACE) gene insertion/deletion polymorphism and ACE inhibitor-related cough: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2014.951328

Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2014.951328

Angioedema induced by angiotensin-converting enzyme inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2014.951328

Impact of the preintervention rate of renal function decline on outcome of renoprotective intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2014.951328

Pharmacogenetics of ACE inhibitor-induced angioedema and cough: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2014.951328

A complicated role for the renin-angiotensin system during pregnancy: highlighting the importance of drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2014.951328

Teratogenicity of angiotensin converting enzyme inhibitors or receptor blockers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2014.951328

Maternal exposure to angiotensin converting enzyme inhibitors in the first trimester and risk of malformations in offspring: a retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2014.951328

An overview of drug-induced acute kidney injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2014.951328

Atherosclerotic renal artery stenosis, ACE inhibitors, and avoiding cardiovascular death

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2014.951328

Cardiovascular endocrinology 1: aldosterone function in diabetes mellitus: effects on cardiovascular and renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2014.951328

Low plasma aldosterone despite normal plasma renin activity in uncomplicated type 1 diabetes mellitus: effects of RAAS stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2014.951328

Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2014.951328

Efficacy and safety of combined vs. single renin-angiotensin-aldosterone system blockade in chronic kidney disease: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2014.951328

Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2014.951328

Evolution of diuretics and ACE inhibitors, their renal and antihypertensive actions--parallels and contrasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2014.951328

Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: nested case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2014.951328

ACE Inhibitors Drug Interactions of Clinical Significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2014.951328

High absolute risks and predictors of venous and arterial thromboembolic events in patients with nephrotic syndrome: results from a large retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2014.951328

Heparin-induced aldosterone suppression and hyperkalemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2014.951328

Enalapril-associated acute renal failure in renal transplants: possible role of cyclosporine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2014.951328

Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2014.951328

Development of prescribing-safety indicators for GPs using the RAND Appropriateness Method

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2014.951328

Quality indicators for medication use in vulnerable elders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2014.951328

Use of clinical decision support systems for kidney-related drug prescribing: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2014.951328

ACE inhibition has adverse renal effects during dietary sodium restriction in proteinuric and healthy rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2014.951328

Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2014.951328

Nifedipine and enalapril equally reduce the progression of nephropathy in hypertensive type 2 diabetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2014.951328

Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2014.951328

Effect of successful hypertension control by manidipine or lisinopril on albuminuria and left ventricular mass in diabetic hypertensive patients with microalbuminuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2014.951328

Effects of amlodipine fosinopril combination on microalbuminuria in hypertensive type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2014.951328

Efficacy and safety of benazepril for advanced chronic renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2014.951328

A random comparison of fosinopril and nifedipine GITS in patients with primary renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2014.951328

Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: the NESTOR Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2014.951328

Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2014.951328

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2014.951328

Preventing microalbuminuria in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2014.951328

Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2014.951328

Aminopeptidase P in individuals with a history of angio-oedema on ACE inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14740338.2014.951328

10.1517/14740338.2014.951328

21 January 2018

Identifiers

DOI

1 reference

2 August 2017

1 reference